Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib ; volume:19 ; number:1 ; day:10 ; month:9 ; year:2019 ; pages:1-13 ; date:12.2019
BMC cancer ; 19, Heft 1 (10.9.2019), 1-13, 12.2019
- Urheber
-
Haan, R. de
Werkhoven, E. van
Heuvel, M.M. van den
Peulen, H. M. U.
Sonke, G. S.
Elkhuizen, P.
Brekel, M. W. M. van den
Tesselaar, M. E. T.
Vens, C.
Schellens, J. H. M.
Triest, B. van
Verheij, M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6121-3
- URN
-
urn:nbn:de:101:1-2020012501075896744744
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Haan, R. de
- Werkhoven, E. van
- Heuvel, M.M. van den
- Peulen, H. M. U.
- Sonke, G. S.
- Elkhuizen, P.
- Brekel, M. W. M. van den
- Tesselaar, M. E. T.
- Vens, C.
- Schellens, J. H. M.
- Triest, B. van
- Verheij, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
PARP inhibitors
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
PARP inhibitors
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma
PARP inhibitors